Results of this trial indicate that dapagliflozin treatment immediately after an acute heart attack reduced adverse cardiovascular and metabolic outcomes. In this interview, Stefan James MD, PhD and Laxmi Mehta MD, FACC, discuss AHA Late-Breaker: DAPA-MI - A Registry-Based Randomized Trial of Dapagliflozin in Patients With Acute Myocardial Infarction Without Diabetes. 

 Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör American College of Cardiology. Innehållet i podden är skapat av American College of Cardiology och inte av, eller tillsammans med, Poddtoppen.